Boston Scientific Cyberattack Threatens 2026 Sales After $1B Guidance Cut

Boston Scientific’s August cyberattack hit a 2026 growth outlook that had already deteriorated sharply. Management’s reported revenue-growth guide fell from 10.5–11.5% in February to 7.0–8.5% in April and 5.5–6.5% in July. The September 8 warning says even that July range is unlikely. For a 2026 earnings model, the shortfall now has two layers: Watchman and U.S. electrophysiology pressure that weakened the base before August, followed by a systems outage that disrupted shipments and widened the miss.

The scale of the pre-cyber reset was large. Boston Scientific generated $20.074 billion of sales in 2025. February’s 10.5–11.5% growth range implied roughly $22.18 billion to $22.38 billion of 2026 sales. July’s 5.5–6.5% range implied about $21.18 billion to $21.38 billion. Because both ends moved down five percentage points, management had removed approximately $1.00 billion from the implied full-year revenue range before the network incident began.

The July cut had an operating explanation. Reuters reported slower growth in the Watchman left-atrial-appendage-closure franchise and tougher competition in U.S. electrophysiology; management said it had underestimated U.S. competitive pressure. Those issues belong to the pre-incident earnings story. The cyberattack created a separate constraint on manufacturing, order processing and shipping.

The half-year arithmetic shows how low the July hurdle had become. Boston Scientific generated $10.646 billion of sales in the first six months of 2026, up 9.5% from $9.724 billion a year earlier. To reach the July full-year range, it needed roughly $10.53 billion to $10.73 billion in the second half. The comparable second half of 2025 produced about $10.35 billion. The July low end therefore required just 1.8% second-half revenue growth, while the high end required about 3.7%.

That trajectory changes attribution. First-half sales had risen 9.5%, yet the July plan already assumed a pronounced second-half deceleration before any cyber disruption. The five-point cut from February to July belongs to the operating reset; the September warning measures an additional shortfall against that lower base. For 2027 estimates, Watchman and U.S. electrophysiology demand are the persistent operating questions, while delayed shipments are the portion of the cyber hit that can still reverse as backlog clears.

On August 25, Boston Scientific identified unauthorized activity that caused a network outage. Its SEC filing says affected systems and applications were used to manufacture products and to process and ship customer orders. The financial transmission is direct: disrupted production and order fulfilment delay the point at which customer demand becomes delivered product and recognized revenue.

By the evening of September 9, manufacturing, order fulfilment and shipping were fully restored. Boston Scientific said products were moving through distribution at or above normal levels and that teams were processing orders from before and during the disruption. Independent assessments had also found no evidence of ongoing threat activity or compromise to product technologies, and management said it did not currently expect a material long-term effect on the company’s financial condition.

Restoration changes the likely shape of the cyber loss. Some revenue can be recovered as backlog converts, making timing more important than the roughly two-week calendar duration of the disruption. Recovery costs and any orders that move beyond year-end still affect 2026 earnings. Yet even a strong backlog recovery would leave the earlier operating reset intact: Watchman and U.S. EP pressure had already taken about $1 billion out of the implied annual sales range.

Boston Scientific will update guidance with third-quarter results on October 28. The cyber incident can determine the incremental shortfall below July’s 5.5–6.5% range. The five-point, roughly $1 billion reduction from February to July came first. The 2026 deterioration now separates cleanly into two parts: a roughly $1 billion revenue reset that preceded the outage, and an incremental cyber shortfall against the already-lowered July base.

Boston Scientific Cyberattack Threatens 2026 Sales After $1B Guidance Cut

Sources

You May Also Like

Subscribe to our Newsletter